COMUNICADO: La Comisión Europea aprueba la ampliación en la indicación de Zonegran® (zonisamida) para su uso en niños con epilepsia

6. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. http://www.ilae.org/Visitors/Documents/Guidelines-epilepsia-12074-2013.pdf [Accessed April 2013]

7. Guerrini R. et al. Safety and potential impact on growth and developmental skills of long-term adjunctive zonisamide therapy in paediatric patients with partial epilepsy. EPNS 2013 abstract 1765

8. Rosati, A. et al. Efficacy of long-term adjunctive zonisamide therapy in paediatric patients with partial epilepsy: results of an open-label extension study of a Phase III, randomised, double-blind, placebo-controlled trial. EPNS 2013 abstract 1768

9. Giorgi, L. et al. Safety of adjunctive zonisamide in paediatric epilepsy patients: results from a pooled analysis of 17 studies. EPNS 2013 abstract 1767

10. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224-2233.

[TAB]
Job code: Zonegran-UK2511a
Date of preparation: October 2013
[FTAB]

CONTACTO: Investigaciones de los medios: Eisai Europe Ltd: Cressida Robson/ Charlotte Andrews, +44(0)7908 314 155/+44(0)7947 231 513,Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net; Tonic LifeCommunications: Frances Murphy/Nicola Lilley, +44(0)207 798 9262 /+44 (0)207 798 9905, frances.murphy@toniclc.com, nicola.lilley@toniclc.com

WhatsAppFacebookTwitterLinkedinBeloudBluesky